Valuation: NEOVACS

Market Cap 4.09T 4.67T 3.77T 3.49T 6.62T 4L 6.73T 45.16T 17.7T 2L 17.55T 17.17T 8L P/E 2023 *
-
P/E 2024 -
Enterprise Value -2L -2L -2L -2L -3L -2.19Cr -3L -22.2L -9L -1.08Cr -9L -8L -3.73Cr EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99%
Yield 2023 *
-
Yield 2024 -
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 01/10/2020
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 28/05/2003
Director/Board Member - 01/05/2020
Chairman - -
Change 5-day change 1-year change 3-year change Capi.($)
-1.00%-1.00% - - 2L
+1.68%+3.19%+3.55%+10.97% 4.94TCr
+0.72%+1.00%+396.18%+624.25% 4.03TCr
+2.54%+0.93%+28.98%-3.62% 3.4TCr
+0.31%+1.74%+18.44%+59.76% 3.36TCr
-2.09%-1.98%+3.21%+33.56% 2.68TCr
-0.63%+0.34% - - 1.72TCr
+0.66%-3.96%+66.85%+127.36% 1.52TCr
-23.90%-21.43%+50.06%+53.83% 1.4TCr
+2.59%-0.49%+15.24%+21.25% 1.34TCr
Average -1.91%-2.30%+72.81%+115.92% 2.71TCr
Weighted average by Cap. -0.60%-0.86%+87.20%+138.87%

Financials

2023 2024
Net sales 5L 6L 5L 5L 9L 5.82Cr 9L 58.91L 23.09L 2.86Cr 22.89L 22.4L 9.9Cr 4L 5L 4L 4L 7L 4.73Cr 7L 47.92L 18.79L 2.33Cr 18.62L 18.22L 8.05Cr
Net income -87.43L -99.95L -80.63L -74.6L -1.42Cr -95Cr -1.44Cr -9.66Cr -3.79Cr -47Cr -3.75Cr -3.67Cr -162.28Cr -3.29Cr -3.76Cr -3.04Cr -2.81Cr -5.33Cr -359.14Cr -5.42Cr -36Cr -14Cr -176.36Cr -14Cr -14Cr -610.89Cr
Net Debt -2L -3L -2L -2L -4L -2.58Cr -4L -26.12L -10.24L -1.27Cr -10.15L -10L -4.39Cr -2L -2L -2L -2L -3L -2.24Cr -3L -22.65L -9L -1.1Cr -9L -9L -3.81Cr
Logo NEOVACS
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
-